Canna~Fangled Abstracts

Differences in the phospholipid profile of melanocytes and melanoma cells irradiated with UVA and treated with cannabigerol and cannabidiol

By September 26, 2023September 27th, 2023No Comments

. 2023 Sep 26;13(1):16121.

doi: 10.1038/s41598-023-43363-9.

Wojciech Łuczaj 1, Izabela Dobrzyńska 2, Elżbieta Skrzydlewska 3
Affiliations 

Abstract

UV radiation inducing mutations in melanocytes might cause melanoma. As changes in lipid composition and metabolism are associated with many types of cancer including skin cancer, we aimed to evaluate the effects of two phytocannabinoids cannabidiol (CBD) and cannabigerol (CBG), on changes in phospholipid and ceramide (CER) profiles induced by UVA irradiation in human melanocytes and melanoma. UVA radiation caused a significant up-regulation PC, PI and SM species and decrease of CERs content in both types of cells, while up-regulation of PEo was only observed in melanocytes. Exposure of UVA-irradiated melanocytes or melanoma cells to CBD and/or CBG led to significant decrease in relative content of PC, PI and SM specie; however, this effect was more pronounced in cancer cells. Interestingly, only in UVA-irradiated melanocytes and not in melanoma, PEo content was lowered after CBD treatment, while CBG led to additional up-regulation of PEo species. CBD and CBG used together caused decrease of zeta potential, inhibiting PS externalization, and different changes in relative contents of CER and SM species of irradiated and non-irradiated melanoma cells. Obtained results are quite promising due to CBD and CBG abilities to partial reverse pro-cancerogenic changes in phospholipid and CER profiles induced by UVA.

References

    1. Jia, Y., Gan, Y., He, C., Chen, Z. & Zhou, C. The mechanism of skin lipids influencing skin status. J. Dermatol. Sci. 89, 112–119 (2018). – PubMed – DOI
    1. Jeong, H., Kim, Y. H., Lee, Y., Jung, S. J. & Oh, S. B. TRPM2 contributes to LPC-induced intracellular Ca2+ influx and microglial activation. Biochem. Biophys. Res. Commun. 485, 301–306 (2017). – PubMed – DOI
    1. Podo, F. et al. Activation of phosphatidylcholine-specific phospholipase C in breast and ovarian cancer: Impact on MRS-detected choline metabolic profile and perspectives for targeted therapy. Front. Oncol. 6, 171 (2016). – PubMed – PMC – DOI
    1. Liu, P. et al. The mechanisms of lysophosphatidylcholine in the development of diseases. Life Sci. 247, 117443 (2020). – PubMed – DOI
    1. Bandu, R., Mok, H. J. & Kim, K. P. Phospholipids as cancer biomarkers: Mass spectrometry-based analysis. Mass Spectrom. Rev. 37, 107–138 (2018). – PubMed – DOI

Leave a Reply